17β-HSD-1基因多态性与子宫内膜腺癌发病风险关系的研究
|
摘要
目的探讨17β-羟基类固醇脱氢酶-1(17β-HSD-1)基因多态性与子宫内膜腺癌发病风险的关系,以期为子宫内膜腺癌的病因学研究和高危人群的筛查积累资料。
研究方法运用等位基因特异性PCR(ASA-PCR)技术分别针对不同的SNP设计6对引物。以病例-对照研究,从41例(实验组)子宫内膜腺癌患者手术切除的新鲜组织标本及同时选取27例(对照组)非子宫内膜腺癌患者门诊刮宫后且经病理证实为正常子宫内膜的新鲜组织标本中提取基因组DNA作为PCR模板,通过PCR扩增,琼脂糖凝胶电泳,检测17β-羟基类固醇脱氢酶-1基因1004位、1322位和1954位点多态性。采用SPSS13.0软件Chi-Square(χ~2)进行数据分析比较对照组和子宫内膜腺癌组之间的差异。
结果子宫内膜腺癌组与对照组17β-HSD-1基因1004位、1322位和1954位SNP表达无显著差别,P值分别是0.944、0.974、0.981。
结论子宫内膜腺癌组与对照组17β-HSD-1基因1004位、1322位和1954位SNP表达无显著差别,以上位点基因多态性可能与子宫内膜腺癌病因学无关。
Objective To investigate the correlation between the17β-HSD-1 gene polymorphisms and risk for endometrial adenocarcinoma,in order to accumulate document for the etiology study and screening of endometrial adenocarcinoma.
Methods Forty-one patients with endometrial adenocarcinoma were selected as study group and twenty-seven healthy women were selected as control group,the samples were collected and genome DNA were extracted as the template of PCR. The single nucleotide polymorphism of 17-beta-hydroxysteroid dehydrogenase-1 gene at sites 1004,1322 and 1954 were studied by allele-specific PCR(ASA-PCR) technique.SPSS13.0 software,Chi-Square(x~2)statistical were used to analysize the discrepancy between the group control and endometrial cancer.
Result There was no significant discrepancy in SNP of 17β-HSD-1 gene at sites 1004,1322 and 1954 between endometrial adenocarcinoma and the control.
Conclusion There is no significant discrepancy of SNP between at gene si-tes1004,1322 and 1954 of 17β-HSD-1 gene between group endometrial ad-enocarcinoma,and the control.It seems that there is no relationship betwe-en the polymorphism of 17β-HSD-1 gene with the etiopathogenisis of en-dometrial adenocarcinoma.
Significance Study the relationship between the gene polymorphism of 17β -HSD with the etiopathogenisis of en-dometrial adenocarcinoma,conduce to further understand the molecule mechanism of tumour orignated,then offter new way for the endometrial adenocarcinoma's prophylaxis,diagnosis and treatment.
研究方法运用等位基因特异性PCR(ASA-PCR)技术分别针对不同的SNP设计6对引物。以病例-对照研究,从41例(实验组)子宫内膜腺癌患者手术切除的新鲜组织标本及同时选取27例(对照组)非子宫内膜腺癌患者门诊刮宫后且经病理证实为正常子宫内膜的新鲜组织标本中提取基因组DNA作为PCR模板,通过PCR扩增,琼脂糖凝胶电泳,检测17β-羟基类固醇脱氢酶-1基因1004位、1322位和1954位点多态性。采用SPSS13.0软件Chi-Square(χ~2)进行数据分析比较对照组和子宫内膜腺癌组之间的差异。
结果子宫内膜腺癌组与对照组17β-HSD-1基因1004位、1322位和1954位SNP表达无显著差别,P值分别是0.944、0.974、0.981。
结论子宫内膜腺癌组与对照组17β-HSD-1基因1004位、1322位和1954位SNP表达无显著差别,以上位点基因多态性可能与子宫内膜腺癌病因学无关。
Objective To investigate the correlation between the17β-HSD-1 gene polymorphisms and risk for endometrial adenocarcinoma,in order to accumulate document for the etiology study and screening of endometrial adenocarcinoma.
Methods Forty-one patients with endometrial adenocarcinoma were selected as study group and twenty-seven healthy women were selected as control group,the samples were collected and genome DNA were extracted as the template of PCR. The single nucleotide polymorphism of 17-beta-hydroxysteroid dehydrogenase-1 gene at sites 1004,1322 and 1954 were studied by allele-specific PCR(ASA-PCR) technique.SPSS13.0 software,Chi-Square(x~2)statistical were used to analysize the discrepancy between the group control and endometrial cancer.
Result There was no significant discrepancy in SNP of 17β-HSD-1 gene at sites 1004,1322 and 1954 between endometrial adenocarcinoma and the control.
Conclusion There is no significant discrepancy of SNP between at gene si-tes1004,1322 and 1954 of 17β-HSD-1 gene between group endometrial ad-enocarcinoma,and the control.It seems that there is no relationship betwe-en the polymorphism of 17β-HSD-1 gene with the etiopathogenisis of en-dometrial adenocarcinoma.
Significance Study the relationship between the gene polymorphism of 17β -HSD with the etiopathogenisis of en-dometrial adenocarcinoma,conduce to further understand the molecule mechanism of tumour orignated,then offter new way for the endometrial adenocarcinoma's prophylaxis,diagnosis and treatment.
引文
[1]连利娟.林巧稚妇科肿癌系[M].4版.北京:人民卫生出版社,2006:452-478.
[2]Henderson,B.E.,and Feigelson,H.S.Hormonal carcinogenesis.Carcinogenesis(Lond.),21:427-433,2000.
[3]Gielen SC,Hanekamp EE,Hanifi-MoghaddamP,et al.Growth regulation and transcrip-tional activities of estrogen and progesterone in human endometrial cancer cells[J].Gynecol Cancer,2006,16(1):110.
[4]Kiyoshi Ito,Hiroki Utsunomiya,Takashi Suzuki,Sumika Saitou,Jun-Ichi Akahira,Kunihiro Okamura,Nobuo Yaegashi,Hironobu Sasano 17-Hydroxysteroid dehydrogenases in human endometrium and its disorders Molecular and Cellular Endocrinology 248(2006) 136-140
[5]Normand,T.,Narod,S.,Labrie,F.,and Simard,J.Detection of,lymorphisms in the estradiol 17-hydroxysteroid dehydrogenase 2 gene at the EDH17B2 locus on 17q11-q21.Hum.Mol.Genet.,2:479-483,1993.
[6]Feigelson,H.S.,McKean-Cowdin,R.,Coetzee,G.A.,Stram,D.O.,Kolonel,L.N.,and Henderson,B.E.Building a multigenic model of breast cancer susceptibility:CYP 17 and HSD 17B1 are two important candidates.Cancer Res.,61:785-789,2001.
[7]Veronica Wendy Setiawan,Susan E.Hankinson,Graham A.Colditz,David J.Hunter,and Immaculata De Vivo,HSD17B1 Gene Polymorphisms and Risk of Endometrial and Breast Cancer.Vol.13,213-219,February 200
[8]Jarabak J.Adams JA.Williams-AshRlan HG,eL al.PLlri cation of a 1713-hydeoxysteroid dehydrogenase of human placenta and studies on its transhydrogenase function.J BioChem,1999,237:345-357.
[9]Luu-e V,Dufort I,Pelletier G,et al Type 5 17beta-hydroxysteroid dehydrOge Ⅱa:its role in the formation of and ∞ s in men.Mol Cell Endocrinol,2001,171:77-82
[10]Peltoketo H.Nokelainen P,Piao YS,et al Two 1713-H.vdroxysteroid dehydrogetmses(17HSDs)of estradiol bio-synthesis:17HSD type 1 and type 7 J Steroid Biochem Mol Biol.1999.69:431-439
[11]Breifiing R,KrazeisenA,MoilerG.et al 17beta-hy&o-teroid dehydrogenaze type 7.an ancient 3-ketosteroid 1-lUc-tase of cholesterogenesis.Mol Cell Endocrinol,2001,171:199-204.
[12]Steckelbroeck S,Stoffel-Wagner B,Reicbeh R,et al Char-acterlzation of 17beta-hydroxysteroid dehydrogenase activity.in brain tissue:testosterone formation in the human tempe ra]lobe.J Neuroendocfinol.1999.11:457-464.
[13]Takeyar-a J,Suzuki T,Hirasawa G.et al 1713-hydroxyste-mid dehydrogenase type 1 and 2 expression in the human fe-tus J Clin Endocr Metb,2000,85:410-416
TwestenW,Holterhus P,Sippe//WG,et aJ ClimeM,eⅡ-docrine,and molecular genetic ndi" in patients with 17beta-hydroxysteroid dehydrogenase deficiency Horm Res.2000.53:26-31.
[14]Castagnetta LA,Carru_ba G,Tra]na A,et al.Expression of different 1713-hydroxysteroid dehydrogenase types and their activities in human pmst-e caner cells.Endocrinology,4876-4882.
[15]Lin SX.Han Q,Azzi A,et al 3D-structure of human es-trogenic 1713-HSDI:binding with various steroids.J Ster-old Blochem Mol Biol_1999.69:425-429 beta-hydroxysteroid dehydrogenase deficiency Horm Res.2000.53:26-31.
[16]Parker SL,Tong T,Bolden S,et al.Cancer statistics CA Cancer J Clin,1996,46(1):5-27.
[17]徐望红,项永兵,金凡,等.上海市区女性生殖系统恶性肿瘤发病趋势分析[J].肿瘤,2003,23(4):268-271.
[18]E N Imyanitov.K P.Hanson.Molecular pathogenesis of bilateral breast cancer.Cancer Letter.2003.191:1.7
[19]Carey AH,Waterworth D。 Patal K,et al Polyeystie ovaries and pre.mature male pattern baldness are associated With one allele of the steroid metabolism gene CYP 17.Htim Mol Genet 1994.3:1873
[20] Franks S,Gharani N,McCarthy M +Candidate genes in polycystic Ovary syndrome.Hum Repord Update,2001,7(4):405-410
[21] Amant F,Moerman P, Neven P, et al.Endometrial cancer[J]. Lan—cet, 2005, 366(9484): 491—505.
[22] Sun H,Enomoto T,Shroyer KR,et al .Clonal analysis and mutations in the PTEN and the K—ras genes in endometrial hyperplasia[J] .Diagn Mol Pathol,2002,11:204-211
[23] Tu Z,Gui L,Wang J,et al .Tumorigenesis of K—ras muta—tion in human endometrial carcinoma via upregulation of estrogen receptor[J].Gynecol Oncol,2006,101:274-279
[24] Berstein LM, Imyanitov EN,Kovalevskij AJ,et al .CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity [J]. Cancer Lett,2004.2O7:191.196
[25] Gan det MM,Lacey JV Jr,Lissowska J,et al .Genetic vari ation in CYP17 and endometrial cancer risk [J].Hum Genet,2008,123:155.162
[26]Singh M,Zaino RJ,Filiaci VJ,et al. Relationship of es—trogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma:a Gynecologic OneologY Group study[J]. Gynecol Oncol,2007,106:325—333
[27] Zhang Y,Liao Q,Chen C,et al.Function of estrogen receptor isofolnls alpha and beta in endometrial carcinoma cells [J].Int J Gynecol Cancer,2006,16:1656—1660
[28] Zhou C,Bae—Jump VL,Whang YE,et al.The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels[J].Gyneeol Oncol,2006,101:305-310
[29] Ueda M,Terai Y,Kanda K,et al.Germline polymorphism of p53 codon 72 in gynecological cancer[J].Gynecol Oncol.2006,100:173—178
[30] Orbo A,Kaino T,Ames M,et al.Genetic derangements in the tumor suppressor gene PTEN in endometrial precancers as prognostic markers for cancer development:a population.based study from northern Norway with long—term follow up[J].Gynecol Oncol,2004,95:82-88
[31]Tao MH,Cai Q,Xu WH,et al.Cytochrome P450 1B1 and catechol.methyhransferase genetic polymorphisms and endometrial cancer risk in Chinese women 1 J 1.CancerEpidemiol Biomarkers Prev.2006,15:2570-2573
[32]Seremak-Mrozikiewicz A,Drews K.Semczuk A,et al.CYP1 Al alleles in female genital cancers in the Polish population[J].Eur J Obstet Gynecol Reprod Biol,2005.118:246-250
[33]Sasaki M,Kaneuchi M,Sakuragi N,et al.Muhiple pro-motets of catecho 1.0-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer[J].Cancer Res,2003,63:3101-3106
[34]Semczuk A,Mal'zec B,Roessner A,et al.Loss of het-erozygosity of the retinoblastoma gene is correlated with the altered pRb expression in human endometrial can cerl J 1.Virchows Arch,2002,441:577-583
[35]Devlin LA,Graham CA,ce JH,et al.Ge maline MSH6 mutations are more prevalent in endometrial cancer patient coho-s than hereditary nou polyposis colorectal cancer cohoas[J].Ulster Med J,2008,77:25-30
[36]Berends MJ,Wu Y,Sijmons RH,et al.Toward new strat-egies to select young endometrial eancer patients for mis-match repair gene mutation analysis [J].J Clin Oncol,2003,21:4364-4370
[37]Geisler JP,Geisler HE,Manahan KJ,et al.Nuclear and Cytoplasmic c-myc staining in endometrial carcinoma and their relationship to survival 1 J 1.Int J Gynecol Cancer,2004,14:133-137
[38]Santin AD,Bellone S,Gokden M,et al.Overexpression of HER-2/neu in uterine serous papillary cancer[J].Clin cancer Res.2002.8:1271-1279
[39]董颖,李挺,王颖,等.端粒酶逆转录酶和c-myc基因在子宫内膜样癌及子宫内膜增生中的表达[J].中华病理学杂志,2004,33:4043
[40]LazOr E,Tudose N,Lazhr DC.Prognostic significance of cerbB2 protein in endometrial cancer f J].Rom J Morphol Embryo 1.1998,44:101-107
[41]Labile F,Luu-The V,Lin SX,et al.Intracrinology:role of the family of 17beta-hydroxysteroid dehydrogenases in human physiology and disease.Mol Endocrinol,2000,25(1): 1-16
[42] Wen W, Cai Q and Shu X O et al, Cytochrome P450 1B1 and Catechol-O-Methyltransferase Genetic Polymorphisms and Breast Cancer Risk in Chinese Women: Results from the Shanghai Breast Cancer Study and a Meta-analysis. Cancer Epindemiology Biomarkers and prevtion, 2005, 14(2): 329-335.
[43]. J.A. Doherty, N.S. Weiss , R.J. Freeman et al,Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2005, 14(2): 357-366.
[44] Vihko, P., Harkonen, P., Soronen, P., Torn, S., Herrala, A., Kurkela, R., Pulkka, A., Oduwole, O., Isomaa, V., 2004. 17 Beta-hydroxysteroid dehydrogenases—their role in pathophysiology. Mol. Cell. Endocrinol. 215, 83-88.
[45] Wu, L., Einstein, M., Geissler, W.M., Chan, H.K., Elliston, K.O., Andersson, S., 1993. Expression cloning and characterization of human 17 -beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. J. Biol. Chem. 268, 12964-12969.
[46] Utsunomiya, H., Suzuki, T., Kaneko, C., Takeyama, J., Nakamura, J., Kimura,K., Yoshihama, M., Harada, N., Ito, K., Konno, R., Sato, S., Okamura, K., Sasano, H., 2001. The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma. J. Clin. Endocrinol. Metab. 86, 3436-3443.
[47] Zeleniuch-Jacquotte, A., Akhmedkhanov, A., Kato, I., Koenig, K.L., Shore, R.E., Kim, M.Y., Levitz, M., Mittal, K.R., Raju, U., Banerjee, S., Toniolo, P., 2001. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br. J. Cancer 84, 975-981.
[48] Sasano, H., Suzuki, T., Takeyama, J., Utsunomiya, H., Ito, K., Ariga, N., Moriya, T., 2000. 17-Beta-hydroxysteroid dehydrogenase in human breast and endometrial carcinoma A new development in intracrinology. Oncology 59, 5-12.
[2]Henderson,B.E.,and Feigelson,H.S.Hormonal carcinogenesis.Carcinogenesis(Lond.),21:427-433,2000.
[3]Gielen SC,Hanekamp EE,Hanifi-MoghaddamP,et al.Growth regulation and transcrip-tional activities of estrogen and progesterone in human endometrial cancer cells[J].Gynecol Cancer,2006,16(1):110.
[4]Kiyoshi Ito,Hiroki Utsunomiya,Takashi Suzuki,Sumika Saitou,Jun-Ichi Akahira,Kunihiro Okamura,Nobuo Yaegashi,Hironobu Sasano 17-Hydroxysteroid dehydrogenases in human endometrium and its disorders Molecular and Cellular Endocrinology 248(2006) 136-140
[5]Normand,T.,Narod,S.,Labrie,F.,and Simard,J.Detection of,lymorphisms in the estradiol 17-hydroxysteroid dehydrogenase 2 gene at the EDH17B2 locus on 17q11-q21.Hum.Mol.Genet.,2:479-483,1993.
[6]Feigelson,H.S.,McKean-Cowdin,R.,Coetzee,G.A.,Stram,D.O.,Kolonel,L.N.,and Henderson,B.E.Building a multigenic model of breast cancer susceptibility:CYP 17 and HSD 17B1 are two important candidates.Cancer Res.,61:785-789,2001.
[7]Veronica Wendy Setiawan,Susan E.Hankinson,Graham A.Colditz,David J.Hunter,and Immaculata De Vivo,HSD17B1 Gene Polymorphisms and Risk of Endometrial and Breast Cancer.Vol.13,213-219,February 200
[8]Jarabak J.Adams JA.Williams-AshRlan HG,eL al.PLlri cation of a 1713-hydeoxysteroid dehydrogenase of human placenta and studies on its transhydrogenase function.J BioChem,1999,237:345-357.
[9]Luu-e V,Dufort I,Pelletier G,et al Type 5 17beta-hydroxysteroid dehydrOge Ⅱa:its role in the formation of and ∞ s in men.Mol Cell Endocrinol,2001,171:77-82
[10]Peltoketo H.Nokelainen P,Piao YS,et al Two 1713-H.vdroxysteroid dehydrogetmses(17HSDs)of estradiol bio-synthesis:17HSD type 1 and type 7 J Steroid Biochem Mol Biol.1999.69:431-439
[11]Breifiing R,KrazeisenA,MoilerG.et al 17beta-hy&o-teroid dehydrogenaze type 7.an ancient 3-ketosteroid 1-lUc-tase of cholesterogenesis.Mol Cell Endocrinol,2001,171:199-204.
[12]Steckelbroeck S,Stoffel-Wagner B,Reicbeh R,et al Char-acterlzation of 17beta-hydroxysteroid dehydrogenase activity.in brain tissue:testosterone formation in the human tempe ra]lobe.J Neuroendocfinol.1999.11:457-464.
[13]Takeyar-a J,Suzuki T,Hirasawa G.et al 1713-hydroxyste-mid dehydrogenase type 1 and 2 expression in the human fe-tus J Clin Endocr Metb,2000,85:410-416
TwestenW,Holterhus P,Sippe//WG,et aJ ClimeM,eⅡ-docrine,and molecular genetic ndi" in patients with 17beta-hydroxysteroid dehydrogenase deficiency Horm Res.2000.53:26-31.
[14]Castagnetta LA,Carru_ba G,Tra]na A,et al.Expression of different 1713-hydroxysteroid dehydrogenase types and their activities in human pmst-e caner cells.Endocrinology,4876-4882.
[15]Lin SX.Han Q,Azzi A,et al 3D-structure of human es-trogenic 1713-HSDI:binding with various steroids.J Ster-old Blochem Mol Biol_1999.69:425-429 beta-hydroxysteroid dehydrogenase deficiency Horm Res.2000.53:26-31.
[16]Parker SL,Tong T,Bolden S,et al.Cancer statistics CA Cancer J Clin,1996,46(1):5-27.
[17]徐望红,项永兵,金凡,等.上海市区女性生殖系统恶性肿瘤发病趋势分析[J].肿瘤,2003,23(4):268-271.
[18]E N Imyanitov.K P.Hanson.Molecular pathogenesis of bilateral breast cancer.Cancer Letter.2003.191:1.7
[19]Carey AH,Waterworth D。 Patal K,et al Polyeystie ovaries and pre.mature male pattern baldness are associated With one allele of the steroid metabolism gene CYP 17.Htim Mol Genet 1994.3:1873
[20] Franks S,Gharani N,McCarthy M +Candidate genes in polycystic Ovary syndrome.Hum Repord Update,2001,7(4):405-410
[21] Amant F,Moerman P, Neven P, et al.Endometrial cancer[J]. Lan—cet, 2005, 366(9484): 491—505.
[22] Sun H,Enomoto T,Shroyer KR,et al .Clonal analysis and mutations in the PTEN and the K—ras genes in endometrial hyperplasia[J] .Diagn Mol Pathol,2002,11:204-211
[23] Tu Z,Gui L,Wang J,et al .Tumorigenesis of K—ras muta—tion in human endometrial carcinoma via upregulation of estrogen receptor[J].Gynecol Oncol,2006,101:274-279
[24] Berstein LM, Imyanitov EN,Kovalevskij AJ,et al .CYP17 and CYP19 genetic polymorphisms in endometrial cancer: association with intratumoral aromatase activity [J]. Cancer Lett,2004.2O7:191.196
[25] Gan det MM,Lacey JV Jr,Lissowska J,et al .Genetic vari ation in CYP17 and endometrial cancer risk [J].Hum Genet,2008,123:155.162
[26]Singh M,Zaino RJ,Filiaci VJ,et al. Relationship of es—trogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma:a Gynecologic OneologY Group study[J]. Gynecol Oncol,2007,106:325—333
[27] Zhang Y,Liao Q,Chen C,et al.Function of estrogen receptor isofolnls alpha and beta in endometrial carcinoma cells [J].Int J Gynecol Cancer,2006,16:1656—1660
[28] Zhou C,Bae—Jump VL,Whang YE,et al.The PTEN tumor suppressor inhibits telomerase activity in endometrial cancer cells by decreasing hTERT mRNA levels[J].Gyneeol Oncol,2006,101:305-310
[29] Ueda M,Terai Y,Kanda K,et al.Germline polymorphism of p53 codon 72 in gynecological cancer[J].Gynecol Oncol.2006,100:173—178
[30] Orbo A,Kaino T,Ames M,et al.Genetic derangements in the tumor suppressor gene PTEN in endometrial precancers as prognostic markers for cancer development:a population.based study from northern Norway with long—term follow up[J].Gynecol Oncol,2004,95:82-88
[31]Tao MH,Cai Q,Xu WH,et al.Cytochrome P450 1B1 and catechol.methyhransferase genetic polymorphisms and endometrial cancer risk in Chinese women 1 J 1.CancerEpidemiol Biomarkers Prev.2006,15:2570-2573
[32]Seremak-Mrozikiewicz A,Drews K.Semczuk A,et al.CYP1 Al alleles in female genital cancers in the Polish population[J].Eur J Obstet Gynecol Reprod Biol,2005.118:246-250
[33]Sasaki M,Kaneuchi M,Sakuragi N,et al.Muhiple pro-motets of catecho 1.0-methyltransferase gene are selectively inactivated by CpG hypermethylation in endometrial cancer[J].Cancer Res,2003,63:3101-3106
[34]Semczuk A,Mal'zec B,Roessner A,et al.Loss of het-erozygosity of the retinoblastoma gene is correlated with the altered pRb expression in human endometrial can cerl J 1.Virchows Arch,2002,441:577-583
[35]Devlin LA,Graham CA,ce JH,et al.Ge maline MSH6 mutations are more prevalent in endometrial cancer patient coho-s than hereditary nou polyposis colorectal cancer cohoas[J].Ulster Med J,2008,77:25-30
[36]Berends MJ,Wu Y,Sijmons RH,et al.Toward new strat-egies to select young endometrial eancer patients for mis-match repair gene mutation analysis [J].J Clin Oncol,2003,21:4364-4370
[37]Geisler JP,Geisler HE,Manahan KJ,et al.Nuclear and Cytoplasmic c-myc staining in endometrial carcinoma and their relationship to survival 1 J 1.Int J Gynecol Cancer,2004,14:133-137
[38]Santin AD,Bellone S,Gokden M,et al.Overexpression of HER-2/neu in uterine serous papillary cancer[J].Clin cancer Res.2002.8:1271-1279
[39]董颖,李挺,王颖,等.端粒酶逆转录酶和c-myc基因在子宫内膜样癌及子宫内膜增生中的表达[J].中华病理学杂志,2004,33:4043
[40]LazOr E,Tudose N,Lazhr DC.Prognostic significance of cerbB2 protein in endometrial cancer f J].Rom J Morphol Embryo 1.1998,44:101-107
[41]Labile F,Luu-The V,Lin SX,et al.Intracrinology:role of the family of 17beta-hydroxysteroid dehydrogenases in human physiology and disease.Mol Endocrinol,2000,25(1): 1-16
[42] Wen W, Cai Q and Shu X O et al, Cytochrome P450 1B1 and Catechol-O-Methyltransferase Genetic Polymorphisms and Breast Cancer Risk in Chinese Women: Results from the Shanghai Breast Cancer Study and a Meta-analysis. Cancer Epindemiology Biomarkers and prevtion, 2005, 14(2): 329-335.
[43]. J.A. Doherty, N.S. Weiss , R.J. Freeman et al,Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2005, 14(2): 357-366.
[44] Vihko, P., Harkonen, P., Soronen, P., Torn, S., Herrala, A., Kurkela, R., Pulkka, A., Oduwole, O., Isomaa, V., 2004. 17 Beta-hydroxysteroid dehydrogenases—their role in pathophysiology. Mol. Cell. Endocrinol. 215, 83-88.
[45] Wu, L., Einstein, M., Geissler, W.M., Chan, H.K., Elliston, K.O., Andersson, S., 1993. Expression cloning and characterization of human 17 -beta-hydroxysteroid dehydrogenase type 2, a microsomal enzyme possessing 20 alpha-hydroxysteroid dehydrogenase activity. J. Biol. Chem. 268, 12964-12969.
[46] Utsunomiya, H., Suzuki, T., Kaneko, C., Takeyama, J., Nakamura, J., Kimura,K., Yoshihama, M., Harada, N., Ito, K., Konno, R., Sato, S., Okamura, K., Sasano, H., 2001. The analyses of 17beta-hydroxysteroid dehydrogenase isozymes in human endometrial hyperplasia and carcinoma. J. Clin. Endocrinol. Metab. 86, 3436-3443.
[47] Zeleniuch-Jacquotte, A., Akhmedkhanov, A., Kato, I., Koenig, K.L., Shore, R.E., Kim, M.Y., Levitz, M., Mittal, K.R., Raju, U., Banerjee, S., Toniolo, P., 2001. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br. J. Cancer 84, 975-981.
[48] Sasano, H., Suzuki, T., Takeyama, J., Utsunomiya, H., Ito, K., Ariga, N., Moriya, T., 2000. 17-Beta-hydroxysteroid dehydrogenase in human breast and endometrial carcinoma A new development in intracrinology. Oncology 59, 5-12.